Gilead Sciences Valuation
Is GILD * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of GILD * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: GILD * (MX$1121) is trading below our estimate of fair value (MX$2316.71)
Significantly Below Fair Value: GILD * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GILD *?
Other financial metrics that can be useful for relative valuation.
| What is GILD *'s n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$81.69b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.7x |
| Enterprise Value/EBITDA | 8x |
| PEG Ratio | 4.6x |
Price to Sales Ratio vs Peers
How does GILD *'s PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 7.4x | ||
REGN Regeneron Pharmaceuticals | 7.7x | 7.0% | US$97.5b |
CSL CSL | 6.2x | 7.3% | AU$133.1b |
VRTX Vertex Pharmaceuticals | 10.5x | 8.9% | US$103.9b |
AMGN Amgen | 5.3x | 4.6% | US$148.8b |
GILD * Gilead Sciences | 3x | 2.2% | Mex$81.7b |
Price-To-Sales vs Peers: GILD * is good value based on its Price-To-Sales Ratio (3x) compared to the peer average (7.4x).
Price to Earnings Ratio vs Industry
How does GILD *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Sales vs Industry: GILD * is good value based on its Price-To-Sales Ratio (3x) compared to the Global Biotechs industry average (11.1x).
Price to Sales Ratio vs Fair Ratio
What is GILD *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate GILD *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | Mex$1,121.00 | Mex$1,413.35 +26.1% | 14.0% | Mex$2,049.03 | Mex$1,168.45 | n/a | 26 |
| Apr ’25 | Mex$1,208.00 | Mex$1,444.55 +19.6% | 12.6% | Mex$2,021.86 | Mex$1,152.96 | n/a | 26 |
| Mar ’25 | Mex$1,228.00 | Mex$1,497.82 +22.0% | 12.5% | Mex$2,062.81 | Mex$1,176.31 | n/a | 27 |
| Feb ’25 | n/a | Mex$1,543.00 0% | 11.9% | Mex$1,989.49 | Mex$1,183.41 | n/a | 27 |
| Jan ’25 | Mex$1,368.00 | Mex$1,530.80 +11.9% | 11.9% | Mex$1,969.70 | Mex$1,171.63 | n/a | 27 |
| Dec ’24 | n/a | Mex$1,564.57 0% | 11.7% | Mex$2,007.80 | Mex$1,228.91 | n/a | 27 |
| Nov ’24 | Mex$1,430.00 | Mex$1,622.48 +13.5% | 11.2% | Mex$2,069.44 | Mex$1,266.64 | n/a | 26 |
| Oct ’24 | n/a | Mex$1,559.33 0% | 10.8% | Mex$1,980.51 | Mex$1,212.21 | n/a | 26 |
| Sep ’24 | Mex$1,300.00 | Mex$1,564.32 +20.3% | 10.3% | Mex$1,977.78 | Mex$1,363.98 | n/a | 24 |
| Aug ’24 | Mex$1,273.18 | Mex$1,542.18 +21.1% | 10.1% | Mex$1,935.30 | Mex$1,295.81 | n/a | 25 |
| Jul ’24 | Mex$1,301.00 | Mex$1,585.39 +21.9% | 9.8% | Mex$1,968.89 | Mex$1,318.30 | n/a | 25 |
| Jun ’24 | Mex$1,346.00 | Mex$1,631.83 +21.2% | 9.8% | Mex$2,026.86 | Mex$1,357.12 | n/a | 25 |
| May ’24 | Mex$1,551.92 | Mex$1,664.22 +7.2% | 8.8% | Mex$2,067.69 | Mex$1,438.39 | Mex$1,121.00 | 25 |
| Apr ’24 | Mex$1,477.86 | Mex$1,709.40 +15.7% | 9.7% | Mex$2,154.85 | Mex$1,442.81 | Mex$1,208.00 | 22 |
| Mar ’24 | Mex$1,490.40 | Mex$1,691.94 +13.5% | 10.4% | Mex$2,110.93 | Mex$1,413.40 | Mex$1,228.00 | 23 |
| Feb ’24 | Mex$1,557.39 | Mex$1,646.22 +5.7% | 12.4% | Mex$2,083.38 | Mex$1,182.46 | n/a | 24 |
| Jan ’24 | n/a | Mex$1,676.24 0% | 13.0% | Mex$2,075.73 | Mex$1,245.44 | Mex$1,368.00 | 24 |
| Dec ’23 | Mex$1,636.00 | Mex$1,575.56 -3.7% | 12.2% | Mex$2,011.35 | Mex$1,206.81 | n/a | 24 |
| Nov ’23 | Mex$1,563.40 | Mex$1,550.23 -0.8% | 12.9% | Mex$1,932.55 | Mex$1,242.35 | Mex$1,430.00 | 24 |
| Oct ’23 | Mex$1,289.48 | Mex$1,418.21 +10.0% | 11.1% | Mex$1,792.58 | Mex$1,115.38 | n/a | 23 |
| Sep ’23 | Mex$1,304.31 | Mex$1,419.23 +8.8% | 11.3% | Mex$1,812.68 | Mex$1,127.89 | Mex$1,300.00 | 23 |
| Aug ’23 | Mex$1,212.00 | Mex$1,435.98 +18.5% | 11.3% | Mex$1,841.69 | Mex$1,145.94 | Mex$1,273.18 | 23 |
| Jul ’23 | Mex$1,267.00 | Mex$1,395.27 +10.1% | 11.3% | Mex$1,802.88 | Mex$1,121.79 | Mex$1,301.00 | 23 |
| Jun ’23 | Mex$1,262.50 | Mex$1,395.67 +10.5% | 11.2% | Mex$1,789.83 | Mex$1,113.67 | Mex$1,346.00 | 25 |
| May ’23 | Mex$1,244.55 | Mex$1,440.94 +15.8% | 11.3% | Mex$1,836.78 | Mex$1,142.89 | Mex$1,551.92 | 24 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.